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The aim of this study was to describe the baseline demographic and clinical characteristics as well as 
the functional status of a prospective cohort of patients with rheumatic diseases assisted by the Brazilian 
Public Health System (SUS). Data for 302 patients receiving tumor necrosis factor α inhibitors (anti-
TNF agents) was collected through a standard form. Among patients, 229 (75.8%) were female and 
155 (51.3%) were Caucasian; the mean age was 50.3 ± 12.8 years, and the mean disease duration was 
9.9 ± 8.7 years. Among them 214 patients (70.9%) received adalimumab, 72 (23.8%) etanercept, and 
16 (5.3%) infliximab. Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) was 1.37 ± 
0.67 for all participants. Poor functional response was associated with female gender, married patients 
and with a score of < 0.6 on the EuroQoL-5 dimensions (EQ-5D). Significant correlation was found 
between the HAQ-DI values, disease activity and quality of life (QOL). The results obtained in this 
study contribute to a better understanding of the clinical and demographic characteristics of patients 
with rheumatic diseases at the beginning of anti-TNF-agent treatment by SUS. Furthermore, our findings 
are consistent with another Brazilian and foreign cross-sectional investigations. This knowledge can be 
of great importance for further studies evaluating the effectiveness of biological agents, as well as, to 
contribute to improve the well-being of the patients with rheumatic diseases.
Uniterms: Rheumatic diseases/treatment/patients profile. Rheumatoid arthritis. Ankylosing spondylitis. 
Psoriatic arthritis. Brazilian public health system. Anti-TNF agents/treatment of rheumatic diseases.
O objetivo do estudo foi descrever as características demográficas e clínicas iniciais, bem como o estado 
funcional de uma coorte de pacientes com doenças reumáticas tratados pelo Sistema Único de Saúde 
(SUS). Dados de 302 pacientes em uso de inibidores do fator de necrose tumoral (agentes anti-TNF) 
foram coletados por formulário padronizado. Desses, 229 (75.8%) eram mulheres e 155 (51.3%) eram 
brancos; a idade média foi 50,3 ± 12,8 anos, e a duração média da doença foi de 9,9 ± 8,7 anos. Entre os 
pacientes 214 (70,9%) usaram adalimumabe, 72 (23,8%) etanercepte e 16 (5,3%) infliximabe. A média 
do Health Assessment Questionnaire-Disability Index (HAQ-DI) foi 1,37 ± 0,67 para a população total. 
Pior resposta funcional estava associada com mulheres, pacientes casados e com um valor de EuroQoL-5 
dimensions (EQ-5D) < 0.6. Correlação significativa foi obtida entre os valores de HAQ-DI, atividade das 
doenças e qualidade de vida. Os resultados obtidos no estudo contribuem para o melhor entendimento 
das características clínicas e demográficas de pacientes com doenças reumáticas iniciando a terapia com 
agentes anti-TNF pelo SUS. Além disso, nossos achados são consistentes com resultados obtidos em 
outros estudos transversais nacionais e estrangeiros. Este conhecimento pode ser de grande importância 
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para estudos futuros que avaliem a eficácia de agentes biológicos, assim como, para contribuir para a 
melhoria do bem-estar das pessoas com doenças reumáticas.
Unitermos: Doenças reumáticas/tratamento/perfil de pacientes. Artrite reumatóide. Espondilite 
anquilosante. Artrite psoriásica. Brasil/Sistema Único de Saúde. Agentes anti-TNF/tratamento de 
doenças reumáticas.
INTRODUCTION
Rheumatoid arthritis (RA), ankylosing spondylitis 
(AS) and psoriatic arthritis (PsA) are chronic inflammatory 
diseases that, if not treated properly, can lead to joint 
destruction and deformity, with subsequent functional 
limitation and a direct impact on patients’ quality of life. In 
addition to the articular manifestations, these diseases may 
present with fatigue, movement loss and extra-articular 
manifestations, such as fever, anorexia and weight loss 
(National Institute for Health and Care Excellence, 2009; 
Brasil, 2013).
The prevalence of RA worldwide is approximately 
1% (American College of Rheumatology, 2002; Canadian 
Agency for Drugs and Technologies in Health, 2006), and 
it is two to three times more common in women than in 
men. If untreated, 20-30% of patients with RA will become 
permanently unable to carry out their routine activities 
three years after diagnosis (Canadian Canadian Agency 
for Drugs and Technologies in Health, 2006). In Brazil, a 
cross-sectional study of rheumatic diseases have evaluated 
the prevalence of RA being 0.46% (Senna et al., 2004). 
Another Brazilian study has estimated the RA prevalence 
ranging to 0.2% to 1.0% (Marques Neto et al., 1993).
AS has a prevalence of 0.05-0.23%, is more frequent 
in the second and third decades of life and primarily affects 
Caucasian individuals who are human leukocyte antigen 
subtype B27 (HLA B27) positive. Men are affected three to 
four times more often than women (Sampaio-Barros et al., 
2007; West, 1949; Gomor, Gyodi, Bakof, 1977; Carbone 
et al., 1992) In Brazil, due to widespread miscegenation, 
it is possible to find mulattos afflicted with AS; however, 
this disease is quite rare in non-mixed black populations 
(Sampaio-Barros et al., 2007). AS greatly affects the 
productivity or functional capacity of an individual 
(Chorus et al, 2002).
PsA has been defined as a psoriasis-associated 
inflammatory arthritis (Moll, Wright, 1973). Psoriasis 
affects 2-3% of the population, while inflammatory 
arthritis occurs in 6-42% of patients with psoriasis 
(Gladman, 1995).
The introduction of biological therapy to the 
treatment of rheumatic diseases significantly changed 
the therapeutic approach to these diseases and the 
results obtained. Drugs such as adalimumab (ADA) and 
infliximab (INF) are recombinant monoclonal antibodies 
that bind to and neutralise the biological activity of tumour 
necrosis factor α (TNF-α). Etanercept (ETA) is a fusion 
protein that also binds to TNF-α and inhibits the action of 
this cytokine.
Anti-TNF agents for which the efficacy and safety 
have been demonstrated in the literature (Lipsky et al., 
2000; ST Clair et al., 2004) have been incorporated into 
the Brazilian Public Health System (Sistema Único de 
Saúde – SUS) since 2002 (Brasil, 2008). The SUS is a 
universal health care system in which the supply of anti-
TNF medications follows a rigorous clinical protocol 
(Brasil, 2013) involving patients’ initial consent to receive 
the drug. However, there is a need for an organised 
pharmaceutical service that would allow an understanding 
of the patients’ characteristics and follow-up information 
regarding the long-term therapeutic responses and any 
intolerance to or adverse events associated with the 
prescribed drugs.
Some Brazilian studies regarding rheumatic 
diseases have evaluated functionality, the majority of it 
in RA patients. The functionality results in these studies 
show that the Brazilian AR population presents moderate 
disability without using a biologic therapy (Pinheiro et 
al., 2013; Da Mota et al., 2012; De Oliveira Junior et al., 
2015; De Azevedo et al., 2008; De Souza et al., 2011; Da 
Mota et al., 2010). Furthermore, some of these studies 
have presented a correlation between functionality results 
and disease activity and quality of life (Da Mota et al., 
2012; De Oliveira Junior, et al., 2015). According, De 
Oliveira Junior et al., 2015, patients who present better 
functionality status in the onset of biologic treatment, tend 
to present a good quality of life result after six month of 
therapy.
Belo Horizonte is the capital of the state of Minas 
Gerais (MG), which is located in the South-eastern 
Region of Brazil. In 2011, 2.967 patients with these three 
rheumatic diseases were being treated with biological 
agents in MG, and 1.280 of them were in the initial stage 
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of treatment (Secretaria de Estado de Saúde do Estado de 
Minas Gerais, 2013).
This study aimed to describe the clinical and 
demographic characteristics as well as the use profile of 
anti-TNF agents in patients with RA, AS and PsA who 
were treated by the SUS in Belo Horizonte. In addition, it 
intended to evaluate the factors related to the functional 
capacity of these individuals at the beginning of treatment.
PATIENTS AND METHODS
This cross-sectional study is an integral part of an 
open prospective cohort involving SUS patients in the 
city of Belo Horizonte, MG, Brazil. The study included 
patients diagnosed with RA, AS and PsA who had 
approved applications for ADA, INF and ETA and who 
received the first dose of the drugs after the initiation of 
the cohort. The data were collected from March/2011 to 
February/2013, and only the first interview (baseline data) 
was considered for the present study.
For approval in the application process, the patients 
must meet the respective specific qualifying criteria: the 
American College of Rheumatology (ACR) 1987 (Arnett 
et al., 1988) for patients with RA; the New York criteria 
(Van Der Linden, Valkenburg, Cats, 1984) for AS patients; 
and the Classification Criteria for Psoriatic Arthritis 
(CASPAR) (Taylor et al., 2006) for patients diagnosed 
with PsA.
According to the Clinical Protocol and Therapeutic 
Guidelines for AR, INF is recommended at a dose of 
3 mg/kg, administered intravenously every 8 weeks; at 
the beginning of the treatment, a loading dose should be 
used in three applications as follows: at baseline and after 
2 and 6 weeks respectively. ETA is recommended at a 
dose of 50 mg, administered subcutaneously once a week. 
ADA is recommended at a dose of 40 mg, administered 
subcutaneously every 2 weeks (Brasil, 2013). The 
Brazilian Ministry of Health has not yet established a 
Clinical Protocol and Therapeutic Guidelines for AS nor 
PsA.
The patients were interviewed and examined when 
the drugs were dispensed by SUS, and the data were 
collected in a standard form and stored in databases. 
The sociodemographic variables assessed were age, sex, 
marital status, education and race.
Regarding the clinical variables, the type and 
duration of the disease since diagnosis were investigated. 
Furthermore, the Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) (Garret et al., 1994) and the 
Clinical Disease Activity Index (CDAI) instruments 
(Aletaha, Smolen, 2005) were used to measure the disease 
activity. The patient’s functional ability was assessed by 
the Heath Assessment Questionnaire-Disability Index 
(HAQ-DI) (Bruce, Fries, 2003), and the overall quality 
of life was assessed by the EuroQoL-5 dimensions (EQ-
5D) (The Euroquol Group, 1990); both instruments were 
validated to Brazilian Portuguese (Ferraz et al., 1990; 
Andrade et al., 2012). The HAQ-DI is a quantitative 
measurement of functionality with the following eight 
categories: hygiene, walking, gripping, arising, reaching, 
dressing and grooming, eating and daily activities. The 
HAQ-DI score assesses the difficulty in performing such 
tasks and ranges from 0 (no difficulty) to 3 (unable to 
perform) (Ferraz et al., 1990). The CDAI is an index for 
disease activity assessment and comprises the evaluation 
of pain and swelling of the shoulder, elbow, wrist, knee, 
metacarpophalangeal and proximal interphalangeal joints 
(Aletaha, Smolen, 2005). The disease activity in AS has 
been evaluated using BASDAI, which is a self-reporting 
tool focused on fatigue, axial pain, peripheral pain, 
enthesopathy and morning stiffness, as assessed by the 
Visual Analogue Scale (VAS) 0-10 (Garret et al, 1994). 
The EQ-5D health questionnaire is a generic tool to assess 
the quality of life that identifies 243 possible states of 
health, based on 5 dimensions: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression, with 3 
alternatives for each (The Euroquol Group, 1990; Lubeck, 
2004).
The data regarding the medications currently in 
use, including non-steroidal anti-inflammatory drugs 
(NSAIDs), disease-modifying antirheumatic drugs 
(DMARDs), corticosteroids and biological agents were 
recorded.
All patients signed an Informed Consent Form for 
participation in the study. The study was approved by the 
Research Ethics Committee of the Federal University 
of Minas Gerais (Comitê de Ética em Pesquisa da 
Universidade Federal de Minas Gerais – COEP-UFMG) 
under No. 0069.0.203.000-11.
Statistical analysis
The descriptive data were presented as means 
[standard deviation (SD)] for continuous variables, and 
as absolute frequencies and percentages for categorical 
variables for the entire study population. Comparisons 
of continuous and categorical variables between groups 
of diseases were obtained using an analysis of variance 
(ANOVA) and the chi-square test, respectively.
In the gender-stratified analysis, Student’s t-test was 
used for the continuous variables, and the Pearson chi-
square test was used for the categorical variables.
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To assess the link between selected variables and the 
functionality of patients initiating treatment, a multiple 
linear regression model was developed using the backward 
stepwise method, i.e. deleting variables until obtaining 
the final model. The HAQ-DI was adopted as a response 
variable, and the independent variables were sex, age, 
marital status, race, disease duration, rheumatic disease, 
biological agent and the EQ-5D data.
A Pearson correlation was performed for each group 
of diseases to test the relationship between the values 
obtained with the HAQ-DI, the quality of life assessment 
(EQ-5D) and disease activity tools (CDAI and BASDAI).
A significance level of 5% was adopted. The 
analyses were performed using the software SPSS 19 for 
Windows (IBM, Chicago, IL, USA).
RESULTS AND DISCUSSION
From March/2011 to December/2013, 302 patients 
who received a first dose of anti-TNF agents at SUS and 
that had agreed to participate were included in the study. 
The population consisted of 208 (68.9%) patients with 
RA, 55 (18.2%) patients with AS and 39 (12.9%) patients 
with PsA.
Table I shows the demographic, clinical and drug use 
characteristics when the drugs were first dispensed. There 
was a predominance of female patients (75.8%), while 151 
patients (51.3%) were Caucasian. The mean age (SD) was 
50.3 (12.8) years, and the mean (SD) disease duration was 
9.9 (8.7) years.
One hundred and six (35.1%) patients had a 
high school-level education. Most participants used 
ADA (70.9%), while 23.8% of the patients used ETA, 
and 5.3% used INF. The proportion of PsA patients 
using INF was higher than in the other two conditions 
(p=0.015). Concomitantly, 131 (43.4%) participants 
used methotrexate (MTX); 204 (67.5%) concomitantly 
used glucocorticoid, and 101 (33.4%) concomitantly 
used NSAIDs. Significant differences regarding the 
concomitant use of medications were found between the 
TABLE I - Baseline demographic and clinical characteristic for all population and According to rheumatic disease
Characteristic All (302) AR (208) PsA (39) AS (55) p-value
Age, mean ± SD years 50,33 ± 12,8 51,62 ± 13,32 52,15 ± 9,96 44,16 ± 10,71 <0,001
Female (%) 229 (75,8) 185 (88,9) 25 (64,1) 19 (34,5) <0,001
White (%) 155 (51,3) 100 (48,1) 25 (64,1) 30 (54,5) 0,161
Disease duration, mean ± SD years 9,85 ± 8,71 10,09 ± 8,36 8,97 ± 7,6 9,53 ± 10,73 0,733
Married (%) 177 (58,6) 120 (57,7) 21 (53,8) 36 (65,5) 0,473
Education 0,288
Illiterate (%) 1,0 (0,3) 1 (0,5) 0 0
Read and write (%) 44 (14,6) 35 (16,8) 5 (12,8) 4 (7,3)
Primary School (%) 56 (18,5) 41 (19,7) 5 (12,8) 10 (18,2)
High School (%) 106 (35,1) 76 (36,5) 13 (33,3) 17 (30,9)
College (%) 88 (29,1) 51 (24,5) 14 (35,9) 23 (41,8)
nMissing (%) 7,0 (2,3) 4 (1,9) 2 (5,1) 1 (1,8)
Current medication
Adalimumab (%) 214 (70,9) 148 (71,2) 26 (66,7) 40 (72,7) 0,805
Etanercept (%) 72 (23,8) 54 (26,0) 8 (20,5) 10 (18,2) 0,422
Infliximab (%) 16 (5,3) 6 (2,9) 5 (12,8) 5 (9,1) 0,015
Methotrexate (%) 131 (43,4) 100 (48,1) 15 (38,5) 16 (29,1) 0,033
Glucocorticoid(%) 204 (67,5) 171 (82,2) 11 (28,2) 22 (40,0) <0,001
NSAIDs (%) 101 (33,4) 76 (36,5) 5 (12,8) 20 (36,4) 0,014
Clinical features
BASDAI, mean ± SD 5,02 ± 2,30 # 5,27 ± 2,26 4,83 ± 2,32 0,370
CDAI, mean ± SD 29,85 ± 16,32 30,56 ± 16,92 26,90 ± 14,80 * 0,208
HAQ-DI, mean ± SD 1,37 ± 0,67 1,45 ± 0,68 1,30 ± 0,64 1,12 ± 0,59 0,003
EQ-5D, mean ± SD 0,59 ± 0,18 0,58 ± 0,18 0,61 ± 0,17 0,63 ± 0,18 0,337
# BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) was applied only for PsA and AS patients; *CDAI (Clinical 
Disease Activity Index) was applied only for RA and PsA patients; NSAIDs (Non-Steroidal Anti-Inflammatory Drug); HAQ-DI 
(Health Assessment Questionnaire-Disability Index); EQ-5D (EuroQol-five dimensions).
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diseases; RA patients used more MTX (p=0.033) and 
corticosteroids (p=<0.001) than the patients with other 
diseases, and PsA patients used less NSAIDs than the 
patients with RA or AS.
The BASDAI values were > 4 for AS and PsA 
patients, suggesting a high disease activity in patients at 
the beginning of treatment. The CDAI values were >22 for 
both RA and PsA patients, which indicate a high disease 
activity, with no significant difference between these 
groups (p = 0.208).
The patients’ functionality, measured with the HAQ-
DI, was assessed at a mean score (SD) of 1.37 (0.67) 
for all of the participants at the beginning of treatment. 
Regarding the HAQ-DI score, the RA patients had a higher 
mean value (SD) of 1.45 (0.68), and the AS patients had 
the lowest mean value at 1.12 (0.59), with a significant 
difference among the three diseases (p=0.003). The mean 
value (SD) of the EQ-5D scores for the entire cohort was 
0.59 (0.18) with no significant statistical difference among 
the three diseases (p=0.337).
The main comorbidities found among the patients 
were systemic arterial hypertension (37.7%), depression 
(21.9%), dyslipidemia (18.5%), osteoporosis (13.6%), 
diabetes (9.3%), obesity (7.0%), chronic obstructive 
pulmonary disease (3.6%) and gastric ulcer (3.3%).
Table II shows the comparison of the baseline 
variables between sexes. The women were older 
(p=0.042), had a higher disease activity as measured by 
CDAI (p=0.039), had poorer functionality (p≤0.001) and 
had a higher frequency of ADA (p=0.034), INF (0.005) and 
corticosteroid (p≤0.001) use compared to men.
Table III shows the final model of factors associated 
with a poorer functional response as measured by the 
HAQ-DI. The characteristics of being female, married and 
having an overall health status <0.6 (as assessed by EQ-
5D) are statistically associated with a poorer functional 
response. The variable of age, although this factor was 
not significantly associated with functionality, was kept in 
the final model because age was considered an important 
variable and had a borderline p-value.
Table IV lists the Pearson correlation coefficients 
between HAQ-DI values and the measurements of disease 
activity and quality of life. A significant correlation 
between the HAQ-DI values and the disease activity and 
quality of life measurements (p<0.01) was observed for 
the three groups of patients evaluated.
DISCUSSION
This cross-sectional study is part of an open 
prospective cohort with Brazilian Public Health System 
patients in the city of Belo Horizonte, Minas Gerais, 
Brazil. Patients with RA, AS and PsA treated at SUS 
were mostly women and Caucasian with a mean age of 
50.3 years. The mean disease duration was 9.9 years, 
reflecting established disease. At the beginning of the 
TABLE II - Patients characteristics according to sex. Data reflecting baseline status
Variable
Female  
n= 229 
Mean ± SD or %
Male  
n=73 
Mean ± SD or %
P
Age, years 51,77 ± 12,80 47,69 ± 12,52 0,042
Disease duration, years 9,85 ± 8,46 9,83 ± 9,52 0,985
CDAI* 30,78 ± 16,70 24,90 ± 14,90 0,039
BASDAI** 5,22 ± 2,37 4,84 ± 2,24 0,432
HAQ-DI, 1,47 ± 0,65 1,07 ± 0,64 <0,001
EQ-5D 0,59 ± 0,18 0,63 ± 0,19 0,088
Adalimumab use 169 (73,8) 45 (61,6) 0,034
Etanercept use 53 (23,1) 19 (26,0) 0,360
Infliximab use 7 (3,0) 5(7,0) 0,005
Methotrexate use 103 (45,0) 28 (38,4) 0,196
Corticosteroid use 173 (75,5) 31 (42,5) <0,001
NSAIDs use 82 (35,8) 19 (26,0) 0,079
*For CDAI (Clinical Disease Activity Index) only 212 female and 40 male patients were assessed; **For BASDAI (Bath 
Ankylosing Spondylitis Disease Activity Index) only 44 female and 50 male patients were assessed); HAQ-DI (Health Assessment 
Questionnaire-Disability Index); EQ-5D (EuroQol-five dimensions); NSAIDs (Non-Steroidal Anti-Inflammatory Drug).
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study, the patients had high levels of disease activity, and 
the functionality characterised them as having moderate 
to severe functional difficulty and an intermediate quality 
of life.
Our data on the participants’ profiles are in 
accordance with a study that implemented a database on 
the use of biological agents in Brazil (BIOBADABRASIL) 
(Titton et al., 2011), which showed a predominance of 
female RA patients with mean disease duration of 10 ± 
8.2 years. A possible explanation for the prevalence of RA 
patients is the absence of an appropriate Clinical Protocol 
and Therapeutic Guidelines publication in Brazil to aid in 
the treatment of patients with AS and PsA.
In Brazil, the use of biological agents is not indicated 
to early disease, DMARD-naïve patients. The similar 
mean disease duration found in the present study and 
in the BIOBADABRASIL study demonstrate that there 
is a trend within the Brazilian population regarding the 
average time that it takes to begin treatment with biological 
agents. Another Brazilian study (Soares et al., 2012) 
with RA patients obtained a mean age and prevalence of 
women similar to the present study. However, that study 
had higher mean disease duration. 
Another BIOBADABRASIL study (Fafá et 
al., 2015), evaluated drug survival and reasons for 
discontinuation of anti-TNF α drugs, in AS and RA 
patients. The study included a large number of patients 
(372 AS, 931 RA) and found similar baseline demographic 
characteristics. For the AS cohort, that study found a mean 
age of 43.7±11.9 years and 80,1% of the participants 
were women. Also, for the RA cohort, the mean age was 
53.2±11.9 years, being the majority of the participants 
female (86%). 
The data from an observational study of RA patients 
conducted in Sweden in 2008 (Karlsson et al., 2008) also 
revealed similar baseline characteristics, with patients 
with a mean age of 56 years and 82% female participants; 
however, the mean duration of disease was also higher, 
14 ± 10 years. Longer mean disease duration can be the 
result of requiring patients to show greater disease activity 
as a condition for the initial drugs delivery, given that the 
clinical disease parameters further evolve over a longer 
TABLE III - Baseline characteristics multivariate predictors of a poor functional status
Baseline variable n β coefficient p 95 % CI
Sex
Female 73 Ref. <0,001 [-0,464 ; -0,181]
Male 229 -0,322
Social status
Married 172 Ref. 0,013 [-0,275 ; -0,033]
Others 125 -0,154
EQ-5D
< 0,60 129 Ref. <0,001 [-0,878 ; -0,635]
≥ 0,60 173 -0,756
Age, years
< 50 142 Ref. 0,065 [-0,009 ; 0,231]
≥ 50 160 0,106  
CI (confidence Interval); EQ-5D (EuroQol-five dimensions).
TABLE IV - Correlation (Pearson r values) between HAQ-DI score, EQ-5D and disease activity instruments according patient group
BASDAI CDAI EQ-5D p-value
HAQ-DI
* 0,648 -0,742 P<0,01
0,591 0,597 -0,711 P<0,01
0,63 ** -0,69 P<0,01
*BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) was not applied to RA patients; **CDAI (Clinical Disease 
Activity Index) was no applied to AS patients; HAQ-DI (Health Assessment Questionnaire-Disability Index); EQ-5D (EuroQol-
five dimensions).
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period of time in the presence of symptoms and due to 
the fact that these diseases are difficult to early diagnose. 
Two observational studies investigating the introduction 
of biological therapy in patients with a disease activity 
score >5.1 as measured by the Disease Activity Score in 28 
Joints instrument (DAS-28), one conducted in Lombardia 
(Fillipini et al., 2010) in 2010 and another one conducted 
in UK in 2008 (Hyrich et al., 2008), found mean disease 
duration values greater than that found in our study, which 
followed the Clinical Protocol and Therapeutic Guidelines 
for RA from the Brazilian Ministry of Health, which 
considers a DAS-28 score >3.2 as the initial parameter of 
disease activity.
The BASDAI and CDAI values revealed a high 
disease activity when an anti-TNF agent was first used, 
which is consistent with the indication to use biological 
medications. Patients presented mean values of HAQ-
DI from moderate to high (Bruce, Fries, 2003). Similar 
functionality and disease activity according to the 
BASDAI were found in a descriptive study of individuals 
with spondyloarthritis in Egypt (Tayel et al., 2012), which 
found BASDAI values >4 and an HAQ-DI value in the 
range of 1-2. Therefore, at the beginning of treatment, 
these patients had moderate to high functional impairment 
and a high disease activity according to BASDAI.
The patients in our study had an intermediate quality 
of life as measured by EQ-5D, given that this score ranges 
from 0-1, being 1 the best possible quality of life. Two 
studies, one in South Korea in 2008 (Choi et al., 2008) and 
another one in the Netherlands in 2010 that were based on 
the DREAM patient register (Kievit et al., 2011) and used 
the same instrument, had similar results when patients 
were evaluated at the beginning of treatment, 0.5 (SD 0.2) 
and 0.56 (SD 0.3) respectively. Thus, it is important to note 
that our study shown similar quality of life results to that 
found in studies conducted abroad.
When comparing groups of patients according to 
their rheumatic diseases, there were differences between 
sex, age and functional capacity that can be related to the 
prevalence of women in the group of RA patients and 
the greater presence of men in the group of AS patients. 
We found that women has poor baseline clinical results 
when compared to men. Regarding gender and age, 
the data from a Norwegian register study conducted in 
2008 (Heiberg et al., 2008) that evaluated the treatment 
compliance rate with anti-TNF agents in RA, PsA and AS 
patients showed that the group of RA patients was older 
than the PsA and AS patient groups. In addition, a higher 
percentage of women was found in the RA group, and a 
higher percentage of men was found in the AS group. That 
study revealed that men have a better functional status than 
women and are younger, which was also observed in the 
present study.
At the beginning of treatment, a poorer functionality 
was associated with female gender, married patients and 
with a poor quality of life. Similar findings were found 
in an observational cohort study performed in the UK in 
2013, in which poorer functionality was found in women, 
patients with advanced age at diagnosis, with a long 
duration of symptoms and those who had a history of 
smoking or previous treatment (Tillet et al., 2013).
Functionality assessment is necessary because it is a 
factor that impacts work absenteeism. In a study conducted 
in Germany (Kruger et al., 2012), patients with a high 
number of absences from work in the previous year due 
to the disease had a worse prognosis.
There was a correlation between functionality and 
the indices of disease activity and quality of life. A positive 
correlation was observed between HAQ-DI and disease 
activity indices (BASDAI and CDAI), and a negative 
correlation between HAQ-DI and EQ-5D score was also 
observed. High BASDAI and CDAI values characterise 
high disease activity; consequently, these high values were 
associated with a poorer functional response.
The patients with a poorer functional response had 
a lower quality of life. An Italian observational study 
(Picchianti-Diamanti et al., 2010) evaluating the quality 
of life using the Short-form 36 Health Status (SF-36) 
questionnaire in RA and PsA patients, conducted in 2010, 
also found a significant positive correlation between 
functionality measured by HAQ-DI and disease activity 
measured by DAS in 44 joints.
This study shows important aspects that reflect 
directly in the social aspects of the diseases and in 
the academic environment and political decisions. As 
mentioned by Cavalcanti 2010, Brazilian patients with 
rheumatic disease suffer with many access barriers, such 
as reduced number of rheumatology units, few medical 
specialists, inadequate transportation and little availability 
of medication in Brazilian National Health System. All 
of these aspects mentioned above can directly influence 
on patient’s prognosis and behavior. Thus, it is important 
to note that our study has considered beyond the direct 
increases in disease severity and activity, the patient’s 
functionality and health-related QOL status.
Given the chronic nature of those diseases, the 
main goals of treatment are to reduce symptoms, preserve 
the functional capacity of patients and improve their 
QOL. Recent studies showed that QOL indicators are 
relevant predictors of functionality and other relevant 
health outcomes in individuals with rheumatic conditions 
(Gordeev et al., 2010, Alava et al., 2013, Ariza-Ariza 
H. A. Oliveira Junior, A. M. Almeida, F. A. Acurcio, J. B. Santos, A. M. Kakehasi, J. Alvares, C. G. S. Dabés, M. L. Cherchiglia716
et al., 2009, Gaujoux-Viala et al., 2013). In Brazil, few 
studies has assessed QOL in patients with RA (Pinheiro 
et al., 2013, Da Mota et al., 2012). Pinheiro et al. (2013) 
conducted a cross-sectional study evaluating QOL and 
functionality results in RA patients. That study found that 
health status deteriorated as disease severity increased 
with worsening disability, pain, fatigue, quality of life and 
perceived general health status. It is important to note that 
we have exactly analysed patients with high functional 
and quality of life impairment. Da Mota et al. (2012) 
conducted a prospective cohort with early rheumatoid 
arthritis patients to investigate the capacity of prediction 
of baseline functionality and QOL measures. The mean 
baseline HAQ score was 1.89 at baseline, improving to 
0.77 by the third year (P<0.0001). Most SF-36 domains 
showed significant improvement except for general state 
and vitality. That study also concluded that biological 
therapy was deemed necessary in 22.5% of patients. The 
initial HAQ and SF-36 scores were not associated with 
clinical remission, bone erosions or the need for biological 
therapy at 36 months. Thus, it is important to consider 
baseline results as potential predictors of clinical features, 
during biological therapy.
The study population was selected through 
convenience sampling. One limitation of this method is 
that only patients able to visit the service participated in 
the study. Thus, more severe cases and older adults may 
not have been included in the study. Although this study 
was not planned to represent the Brazilian population, 
what can be considered a limitation, its results reflect 
the impact of the knowledge of the diseases and in living 
with them. Furthermore, we present similar clinical 
and demographic results compared to another Brazilian 
studies (Pinheiro et al., 2013; Da Mota et al., 2012, De 
Oliveira Junior et al., 2015; De Azevedo et al., 2008; De 
Souza et al., 2011; Da Mota et al., 2010). All of these 
studies have predominantly presented patients with RA, 
women, married and Caucasians. In addition, in all of it 
the participants presented moderate to severe disability as 
measured by HAQ-DI.
CONCLUSION
The present study evaluated the use profiles of 
anti-TNF agents in RA, PsA and AS patients treated by 
Brazilian Public Health System. The results showed that 
patients with one of these three diseases had a high disease 
activity at the start of biological therapy. Patients with RA 
had a poorer functional status than patients with PsA and 
AS. Furthermore, being female, being married and having 
a quality of life value <0.6 as measured by EQ-5D was 
associated with a poorer functionality at the beginning 
of treatment. In countries with a universal health care 
system, as in Brazil, it is crucial to understand the patients’ 
characteristics and the results of incorporating this 
therapeutic modality (anti-TNF agents). This knowledge 
can assist in ensuring excellent service to the population 
and enable the optimisation of public resources use, 
improvements in pharmaceutical services and planning 
of future actions. Future analyses entailing a prospective 
follow-up will be performed, given that an observational 
and prospective study is in progress.
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